| Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. “The first quarter of 2025 reflected steady progress across our clinical and operational priorities,” said Robert Lisicki, Chief Executive Offi. |
businesswire.com |
2025-05-08 10:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. “In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le. |
businesswire.com |
2025-03-25 08:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio to Present at the Leerink Partners Global Healthcare Conference |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation. |
businesswire.com |
2025-02-24 08:30:00 |
Czytaj oryginał (ang.) |
| Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) |
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-01-24 12:36:13 |
Czytaj oryginał (ang.) |
| Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults. |
businesswire.com |
2024-12-23 08:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen. |
businesswire.com |
2024-11-25 08:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A. |
businesswire.com |
2024-11-14 18:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. We've worked closely with our contract research organization (CRO) to. |
businesswire.com |
2024-11-07 08:30:00 |
Czytaj oryginał (ang.) |
| Zura Bio to Participate in Two Upcoming Investor Conferences in November |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET. |
businesswire.com |
2024-10-30 08:30:00 |
Czytaj oryginał (ang.) |
| CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology |
SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T. |
businesswire.com |
2024-09-03 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Undervalued Biotech Stocks With Breakout Potential |
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies. |
investorplace.com |
2024-07-19 10:00:00 |
Czytaj oryginał (ang.) |
| The 3 Most Undervalued Biotech Stocks to Buy in July 2024 |
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. |
investorplace.com |
2024-07-12 10:08:00 |
Czytaj oryginał (ang.) |
| Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024 |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co. |
businesswire.com |
2024-06-14 10:00:00 |
Czytaj oryginał (ang.) |
| Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists. |
businesswire.com |
2024-06-06 10:00:00 |
Czytaj oryginał (ang.) |
| Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106. |
businesswire.com |
2024-06-03 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know |
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-05-31 14:56:07 |
Czytaj oryginał (ang.) |
| Zura Bio Announces Participation in June Investor Conferences |
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetin. |
businesswire.com |
2024-05-29 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks to Buy Now: May 2024 |
Penny stocks to buy carry a considerable amount of risk. That's why we include the disclaimer at the tail-end of this article. |
investorplace.com |
2024-05-24 10:18:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84% |
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-05-15 14:55:57 |
Czytaj oryginał (ang.) |
| Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know |
Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-05-14 17:01:32 |
Czytaj oryginał (ang.) |